
GSK remains resilient on tariffs as Q1 sales rise 4%
GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it posted a 4% rise in Q1 2025 sales to £7.52bn ($10.05bn), driven by growth in speciality medicines despite weaker vaccine revenues. The …